BioSpace News Archive

CureLab Oncology, a clinical-stage biotech company, has filed a patent application with worldwide potential for a revolutionary wound-healing therapy based on its p62/SQSTM1 DNA plasmid.

KalVista Pharmaceuticals, Inc., announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema.

Optinose announced that XHANCE® has been added to Express Scripts’ national formularies, including the National Preferred, Flex, and Basic formularies, among the largest commercial formularies in the U.S. with more than 24 million lives.

Tonix Pharmaceuticals Holding Corp. today announced it has entered into a placement agency agreement for the purchase and sale of approximately 7,060,918 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.57 per share (or $0.569 per pre-funded warrant in lieu thereof).

GRI Bio, Inc. today announced that the Korean Intellectual Property Office (KIPO) has granted Patent No. 10-2665487 titled, “Prevention and Treatment of Inflammatory Conditions.”

Quanta Therapeutics announced the advancement of two clinical trials from its pipeline of KRAS-directed drug candidates.

10x Genomics, Inc., a leader in single cell and spatial biology, announced that its Xenium In Situ platform was used in a study published in the Journal of Dental Research, offering novel insights into cellular mechanisms regulating the formation of the secondary palate.

Alveo Technologies, Inc. announced that rigorous development and testing has demonstrated that the Flockscreen LAMP Avian Influenza Molecular Test can accurately detect the presence of virus in both cloacal and oropharyngeal samples from poultry with comparable limit of detection, sensitivity and specificity.

GT Biopharma, Inc. today announced FDA clearance of its IND application for GTB-3650, allowing the company to proceed with a Phase 1 clinical trial, which is anticipated to start in second half of 2024.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company”), a Health Canada-approved, GMP-compliant pharmaceutical drug manufacturer specializing in the controlled substances MDMA and botanical psilocybin, is pleased to announce the launch of OptiMed